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1. Introduction 
The 7th biennial Hatter Cardiovascular Institute workshop, comprising of 21 leading basic science and 
clinical experts, was held in South Africa in August 2012 to discuss the current cutting edge status of 
cardioprotection and the application of cardioprotective modalities in the clinical management of 
myocardial ischaemia/reperfusion injury in the context of acute coronary syndromes and cardiac 
surgery.  The meeting,  chaired by Professor Derek Yellon and Professor Lionel Opie, was run to a 
format of previous Hatter Cardiovascular workshops with data presented by proponents followed by 
discussion and debate by the faculty. 
2. Novel therapeutic targets 
2.1. Microparticles in Cardioprotection 
Sean Davidson and Derek Yellon described their recent foray into the burgeoning field of 
endogenous nanoparticles. These particles, exosomes and microparticles, are released into the 
blood from multiple cell types including activated platelets and epithelial and endothelial cells. They 
are thought to carry microRNA and mRNA with the potential for genetic exchange between cell 
types, as well as transport of signalosomes and even cell-surface receptors [1], all of which have the 
potential for delivering signals to the myocardium that modulate inflammation, angiogenesis or 
cardioprotection. They presented data confirming and quantifying the presence of these particles in 
rat and human plasma, and showed that administration of purified microparticles leads to 
attenuation of infarct size when administered to Langendorff-perfused rat heart and reduced cell 
death in cardiac-derived HL-1 cells subjected to simulated ischaemia/reperfusion. Fluorescently-
labeled microparticles also show increased incorporation into HL-1 cells. Intriguingly, they also 
demonstrated that microparticle numbers can be altered under certain conditions [or “by certain 
treatments”], leading to their proposal that it may be possible to harness them for clinical purposes.  
This preliminary work was considered very interesting, although a number of questions remained – 
particularly as to the parent cell-type of the microparticles released by remote conditioning and the 
efficacy of uptake within the myocardium. Moreover, at this time, it is unclear as to the mechanism 
of protection, but this is the subject of on-going study. 
2.2. Mitochondrial morphology 
Derek Hausenloy and Derek Yellon presented the latest data looking at the role of mitochondrial 
morphology in the context of ischaemia/reperfusion injury, with the hypothesis that preventing 
mitochondrial fragmentation, or fission, during ischaemia/reperfusion injury would lead to a more 
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cardioprotected phenotype. In cardiac-derived HL-1 cells promotion of mitochondrial fusion proteins 
such as mfn-1 and mfn-2, or using a dominant negative mutation of the mitochondrial fission 
protein, Drp1, promoted mitochondrial fusion, and delayed the time to mitochondrial permeability 
transition pore (mPTP) opening in response to reactive oxygen species generating laser-light 
exposure in TMRM loaded cells. Similarly, a pharmacological inhibitor of Drp1 was found to be 
cardioprotective in the adult rat heart following ischaemia/reperfusion injury. Combined Mfn-
1/Mfn-2 knockout adult hearts demonstrated increased mitochondrial fragmentation and the hearts 
demonstrated a dilated cardiomyopathy. Data was also shown examining the role of DJ-1 in the 
heart. Mutations in this protein induce mitochondrial dysfunction and are responsible for a genetic 
form of Parkinson’s disease. Data was shown that over-expressing this protein in a cardiac cell-line 
induce mitochondrial elongation, delayed mPTP opening, and reduced cell death following simulated 
ischaemia/reperfusion injury.  In the adult heart, , the DJ-1 deficient heart had greater mitochondrial 
fragmentation concomitant with increased susceptibility to ischaemia/reperfusion injury. 
Interestingly, these hearts were also partially resistant to the protection elicited by ischaemic 
preconditioning. 
The data was found to be very interesting, although the link between mitochondrial fusion and 
mPTP function is currently unclear – and there are technical challenges in terms of determining 
mitochondrial morphology in adult cardiac myocytes when compared to other cell types given the 
highly structured nature of the myocyte and multiple mitochondrial populations (subsarcolemmal, 
interfibular and perinuclear). 
2.3. Platelets as a target for cardioprotection 
Antiplatelet therapy in the form of P2Y12 inhibitors such as clopidogrel and prasugrel are an integral 
part of the immediate management of ACS. James Downey presented data that these agents have 
an additional pleiotrophic effects in the form of recruiting cardioprotective signalling that is 
dependent upon the presence of platelets, but independent of their impact upon platelet function 
and aggregation. These drugs, including the intravenous P2Y12 inhibitor, cangrelor, demonstrably 
attenuate infarct size when administered before reperfusion – a protective effect dependent upon 
the recruitment of adenosine A2B receptors, signalling reactive oxygen species (ROS) formation, 
reperfusion injury salvage kinases (RISK) and mitochondrial KATP (mKATP). Interestingly, P2Y12 
inhibitors are not additive to ischaemic conditioning, suggesting a conditioning-like protective 
mechanism. Given clinical data showing the genuine benefits of adding P2Y12 inhibitors to aspirin 
and heparin in the management of ACS (these agents themselves do not induce cardioprotection), 
leads to the speculation that there may be a clinical cardioprotective element to the benefits 
observed – above and beyond the antiplatelet effect for which these drugs were originally designed. 
During the discussion of this data, it was observed that there had been a significant shift in the 
adoption of various P2Y12 inhibitors during the lifetime of many of the clinical trials undertaken to 
study the efficacy of conditioning protocols – perhaps implicating a potential confounder to the 
outcome of more recent studies. This phenomenon would deserve further investigation and 
retrospective analysis of previous trial data to ascertain any impact of P2Y12 inhibitors on infarct 
limitation. 
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2.4. Matrix metalloproteinases and cardioprotection 
Matrix metalloproteinases (MMPs) have been extensively studied in the context of vascular injury 
and in ventricular remodelling following ischaemia/reperfusion injury. However, more recently, 
MMPs have been demonstrated to have intracellular targets – cytoskeletal[2, 3], contractile[4, 5] 
and potentially also in terms of cell survival and cell death pathways[6, 7]. Robert Bell and Derek 
Yellon presented data demonstrating that not only does MMP inhibition at reperfusion attenuate 
infarction in both in-vitro and in-vivo preparations, but the protection observed is additional to that 
seen following targeted deletion of the cyclophillin-D component of the mPTP. The pharmacological 
agent used, ilomastat, had no direct inhibitory effect upon mPTP opening in response to ROS 
exposure – further suggesting a conditioning-independent mechanism of protection. Interestingly, 
MMP inhibition with ilomastat did result in increased phosphorylation of Akt, ERK and serine 9 of 
GSK-3. Whether this is mechanistic is currently unclear – and the discussion centred on potential 
mechanisms that could be further investigated in due course. 
2.5. Mitochondrial connexins 
Connexin (Cx) 43 has long been associated with gap junction function and is found associated with 
mitochondria as a consequence of preconditioning signalling. Rainer Schulz presented the latest data 
from his lab regarding the role of Cx43 in preconditioning signalling. The C-terminus of the Cx43 
protein has been found to be the target for multiple post-translational modifications by kinase 
mediated phosphorylation (PKA, Src, MAPK, PKC, CKI and Akt) and S-nitrosylation. Recruitment of 
Cx43 appears to lead to mKATP opening, and subsequent recruitment of preconditioning signalling 
through ROS generation. While Cx43 appears not to be involved in postconditioning, there is data to 
suggest that inhibition of Cx43 leads to a lower threshold to opening of the mPTP in response to 
calcium. 
2.6. Preconditioning mitochondria – implications for cardioprotection 
Marisol Rulz-Meana presented data revealing that it is possible to directly condition mitochondria in 
isolation of the intact myocyte, preserving complex 1 and 2 function, mimicking the mitochondrial 
respiratory preservation seen in intact heart following ischaemic preconditioning. The ability to 
preserve complex 1 respiration in mitochondria was independent of mKATP function and was still 
evident even in mitochondria isolated from cyclophillin-D knock out hearts. Interestingly, the data 
demonstrated that differing mitochondrial populations had variable capacity to be preconditioned, 
which appeared to correlate with the presence or absence of Cx43: Cx43 is largely found in 
subsarcolemmal mitochondria which can be conditioned, versus the relatively deplete interfibral 
mitochondria which demonstrated little capacity to preserve complex 1 and 2 respiration following 
conditioning. Moreover, Cx43 knockouts show no preservation of complex 2 respiration following 
ischaemic preconditioning. 
The mechanism of mitochondrial conditioning was unclear: during the discussion oxidative 
modification of a cysteine residue of Cx43 during preconditioning was speculated along with the 
suggestion that there may still be kinase signalling activity within isolated mitochondria that may go 
some way to explaining the alterations of oxidative metabolism within preconditioned mitochondria. 
2.7. Beta blockade and cardioprotection 
The role of beta blockers and cardioprotection had been investigated in the past, and the data at 
that time felt unconvincing, but new work from Borja Ibanez’s group suggests a new direction in 
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studying a potentially cardioprotective role for beta blockade in ischaemia/reperfusion injury. In 
recent work, intravenous metoprolol was found to attenuate ischaemia/reperfusion injury 
concomitant with phosphorylation of Akt and attenuation of caspase-3. The postulated explanation 
for this protective effect was through activation of a recently characterised 3 Gi/o-coupled receptor, 
activation of which has been shown to increase the bioavailability of nitric oxide through endothelial 
nitric oxide synthase. Data was presented revealing that 3 agonists result in significant attenuation 
of ischaemia/reperfusion injury (improved salvage index by cardiac magnetic resonance imaging 
(CMR)), improved left ventricular ejection fraction through both echo and CMR in pig, and similar 
improvements in viability seen in isolated cardiac myocytes. In mouse, knockouts of 3 show no such 
protection. 
During the discussion, it was noted that similar results have also been seen using nebivolol[8], which 
recruits nitric oxide synthesis through 3 receptor activation. Curiously both the data presented and 
the nebivolol study appear in contrast to earlier data using various beta blockers (summarised by 
Hearse, Yellon and Downey[9]), and the reason for the anomaly remains unclear. Other questions 
arose regarding the density of 3 receptors in human myocardium, which at the present time is 
unknown, but work continues to further characterise this potential mechanism of protection and the 
potential clinical benefits in man. 
3. Translating cardioprotection for clinical benefits 
3.1. Insulin as an agent to protect against ischaemia-reperfusion injury 
Lionel Opie presented an overview of metabolic therapy for acute myocardial infarction: following 
acute anterior injury, adrenergic overdrive switches the substrate for myocardial metabolism from 
glucose to free fatty acids, which is deleterious in terms of long term myocardial viability. Sodi-
Pallares et al were amongst the first to describe the benefits of glucose/insulin/potassium (GIK) 
therapy in the context of acute myocardial infarction in 1962,[10] and has been an area of interest 
revisited many times over the following decades. One key aspect of insulin therapy however is the 
need for it to be administered early. In the recently reported Immediate Myocardial Metabolic 
Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial[11], 
GIK was administed prior to admission to hospital in the ambulance and continued for 12 hours 
thereafter, and therefore present during early reperfusion. While the trial failed to meet its primary 
endpoint of progression to myocardial infarction, there was a significant reduction in the secondary 
endpoint, the composite of prehospital or in-hospital cardiac arrest or in-hospital mortality: 6.1% 
with GIK versus 14.4% with placebo (OR, 0.39; 95% CI, 0.18-0.82; P = .01).[11] Glucose, 
glucose/insulin and glucose/insulin/potassium has been found to be protective in all species studied, 
including man, with benefits too in terms of preservation of sinus and sino-atrial node function[12].  
The key point during the discussion of this presentation was the need for very early administration 
required for insulin’s efficacy – both in terms of correcting the acute metabolic reaction to 
myocardial infarction, and in terms of recruitment of protective signalling cascades and modulation 
of mPTP opening. 
3.2. Preconditioning – where do we go from here? 
Ten years since presenting the original data showing the experimental evidence of ischaemic 
postconditioning, Jake Vinten-Johansen reviewed the data showing how this phenomenon has 
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progressed from the bench to the bed side, with evidence that not only does postconditioning result 
in attenuation of cell death by reducing by necrosis and apoptosis, but also ameliorates neutrophil 
adherence and microvascular obstruction through RISK pathways and inhibition of mPTP opening. 
Recent data has also inferred the presence of a delayed postconditioning phenomenon,[13, 14] and 
further exploration and characterisation of this phenomenon is required which may represent a later 
onset of inflammation and neutrophil infiltration. In terms of future targets for cardioprotection, the 
interaction between endothelium, neutrophils and platelets were discussed in terms of attenuating 
microvascular obstruction and post-infarction inflammation. The potential development of 
cathether-based devices for deploying ischaemic postconditioning and myocardial hypothermia 
were suggested as novel new technologies to induce cardioprotection in patients undergoing 
primary percutaneous intervention. 
The discussion centred on the proposed model of two waves of reperfusion injury, with the late 
phase being mediated by inflammatory and gene-transcription mediated cell damage, which could 
be amenable to a late postconditioning protocol. It was suggested that work be transferred to a 
larger animal model, as small rodents were felt to exhibit very rapid resolution of injury, and 
therefore more likely to be reflective of the injury observed following acute myocardial infarction in 
man. 
3.3. DPPIV inhibitors and GLP-1 analogues – novel cardioprotective and antidiabetic 
agents 
Richard Shannon presented data regarding DPPIV inhibitors and GLP-1 analogues, which 
independent of their anti-diabetic properties, appear capable of inducing cardioprotection via g-
protein coupled receptors that also demonstrate Gs/Gi switching through -arrestin. GLP-1 appears 
negatively ionotropic, independent of glucose uptake. Interestingly, two peptide analogues, 7-36 
and 9-36, demonstrate differing properties which were either p38 MAPK dependent/NO 
independent or p38MAPK independent/NO dependent respectively. Both markedly attenuated free 
fatty acid utilisation by mitochondria without alteration of state 3 respiration, and also demonstrate 
some evidence of mitochondrial respiratory chain uncoupling. Interestingly, DPPIV inhibition was not 
cardioprotective at levels of normoglycaemia, unlike the protective properties of GLP-1 to improve 
post-ischaemic contractile recovery (REF)?. 
These classes of agents would appear to have considerable potential in the management of both 
diabetes and in cardioprotection. Whether DPPIV inhibitors would be cardioprotective in conditions 
of hyperglycaemia is currently unknown. 
3.4. Ischaemic and pharmacological postconditioning: clinical application 
Reinier Beeuwkes started this session describing a novel substance, CMX-2043, a lipoic acid, that 
appears to have cardioprotective properties through recruitment of Akt. CMX-2043 has recently 
been through phase 2a trial and shown to be safe in the context of elective percutaneous 
intervention, and demonstrated some promise in attenuating troponin-release when administered 
15-120minutes prior to the intervention.  
David Garcia-Dorado provided an up-date on the soon to be reported Myocardial Protection With 
Adenosine During Primary Percutaneous Coronary Intervention in patients With STEMI (PROMISE) 
trial (clinical trial number NCT00781404). Designed to evaluate the safety and efficacy of a brief 
intracoronary infusion of adenosine administered at the time of reperfusion, and to assess the drug’s 
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efficacy to limit infarct size and left ventricular remodelling in patients undergoing primary 
percutaneous intervention for ST elevation myocardial infarction, this multicentre, prospective, 
randomised, placebo-controlled, double-blind study recruited 200 patients older than 18 with ST 
elevation, without prior myocardial infarction receiving primary PTCA within 6 hours after symptom 
onset. Infarct size and risk zone will be assessed by CMR, and change of left ventricular ejection 
fraction and end diastolic diameter assessed at 6 months. Only very preliminary data was available 
by the time of the workshop, but the full data set is expected to be available by  September 2012. 
The Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients (CIRCUS) trial update 
was presented by Michel Ovize (trial number NCT01502774). This is a multicentre, randomised and 
double blinded trial designed to compare cyclosporine versus placebo administered as an 
intravenous bolus prior to restoration of blood flow by percutaneous intervention. The study 
investigators are currently recruiting at 1 per month, with over 400 patients already recruited and 
enrolment is expected to continue for another year. The primary end-point is combined incidence of 
total mortality, hospitalization for heart failure and LV remodeling (defined as an increase of LV end-
diastolic volume > 15% by transthoracic echocardiography), with secondary end-points including all-
cause mortality, cardiovascular death, heart failure, unstable angina or stroke. 
Hans Erik Bøtker presented an update on the Effect of Remote Preconditioning in Primary 
Percutaneous Intervention of Acute ST Elevation Myocardial Infarction (CONDI) trial (NCT00435266). 
This randomised single blinded trial used a pressure cuff inflations to induce remote conditioning (4 
cycles of 5 minutes ischaemia, 5 minutes reperfusion) in the transit ambulance prior to the arrival at 
the primary intervention centre following diagnosis of ST elevation myocardial infarction. The 
investigators  recruited 333 patients divided into treatment and placebo groups (167 and 166 
respectively). Median salvage index was 0·75 (IQR 0·50—0·93, n=73) in the remote conditioning 
group versus 0·55 (0·35—0·88, n=69) in the control group, with median difference of 0·10 (95% CI 
0·01—0·22; p=0·0333); mean salvage index was 0·69 (SD 0·27) versus 0·57 (0·26), with mean 
difference of 0·12 (95% CI 0·01—0·21; p=0·0333). Moreover, there was an improvement in 
improvement in major adverse coronary and cerebral events (MACCE) in the RIPC group, presenting 
as an initial benefit and persisting over the subsequent 2 years. Therefore, it was found that remote 
ischaemic conditioning before hospital admission increased myocardial salvage, and had a 
favourable safety profile. 
The Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery (ERICCA) trial 
was presented by Derek Hausenloy. This randomised, single-blinded, multicentre clinical trial 
compared 4 cycles of 5 minutes ischaemia, 5 minutes reperfusion of the upper limb induced by 
pressure cuff inflation, prior to cardiac surgery (coronary artery bypass ± valve replacement), with 
the primary outcome of combined Cardiovascular Death, MI, Revascularisation and Stroke. 
Secondary end-points include peri-operative myocardial injury, LV ejection fraction, acute kidney 
injury, all-cause death, length of ITU stay and quality of Life. So far, the investigators had recruited 
382 out of a targeted 1600 patients over 18 sites, with the aim to complete recruitment by October 
2013, with results anticipated by December of that year.  
3.5. Analysis of existing clinical evidence for conditioning 
Gerd Heusch undertook to look at the translational clinical data centring upon cardioprotection and 
conditioning. Interestingly, of the clinical studies identified, almost all show an improvement of 
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cardiac enzyme release in the context of ischaemic preconditioning in coronary artery bypass 
grafting, ischaemic postconditioning in percutaneous intervention for ST elevation MI and remote 
ischaemic conditioning for both coronary artery bypass grafting and percutaneous invervention. The 
one common element identified underlying negative trial data in surgery was the concomitant use of 
propafol. Other typical confounders that may influence clinical outcome are co-morbidities such as 
diabetes, but an overlooked factor is the coronary vasculatureboth in terms of function and 
pathology: slow reperfusion is itself cardioprotective, and microembolisation (that occurs following 
dispersal of the occlusive coronary thrombus) can attenuate preconditioning’s protection. [15] 
Experimental microembolisation with inert microspheres of 40 m diameter, can increase infarct 
size by up to 15%, predominantly through deposition in the border zone surrounding the infarcted 
myocardium, although interestingly ischaemic postconditioning tends to ameliorate microsphere 
border zone deposition, perhaps suggesting preservation of microvascular function. 
While ischaemic conditioning appears to have robust supporting clinical data, pharmacological 
conditioning, except where the end-effector, the mPTP, has been targeted (cyclosporine), has been 
rather disappointing . It was speculated that the transient ischaemic stimulus is more likely to recruit 
the full conditioning response, rather than a highly selective pharmacological trigger which may 
recruit only limited signalling. 
Over all, it was felt that many of the early phase 2 and 3 trials of ischaemic conditioning had shown 
great promise, and perhaps the lack of general clinical adoption of conditioning was rather more 
dependent upon the lack of significant clinical outcome trials – a void that hopefully will be filled 
once the current on-going clinical trials (as mentioned above) are reported. 
4. Conclusions 
The workshop has offered a preview of a number of original approaches to tackle cardioprotection 
in the future, from novel concepts in signal transmission both in the context of remote conditioning 
and platelet-derived signalling, through mPTP-independent cardioprotective signalling, to 
mitochondrial recruitment as an end-effector in the experimental setting – both in terms of mPTP 
function and mitochondrial morphology. In clinical translation, there are a number of exciting trials 
currently undergoing recruitment and provide hard primary outcome data that will that will 
hopefully provide evidence that conditioning is an efficacious approach in man that will add to the 
data already coming from completed trials that have been discussed. Overall, the participants were 
optimistic regarding the future of cardioprotection as a potential useful tool in the management of 
patients with myocardial ischaemia, to further augment the interventions and therapies already 
available to the clinician. 
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